Psychiatr Serv 55:1006-1013, September 2004
© 2004 American Psychiatric Association
Relationship Between Antipsychotic Medication Treatment and New Cases of Diabetes Among Psychiatric Inpatients
Leslie Citrome, M.D., M.P.H.,
Ari Jaffe, M.D.,
Jerome Levine, M.D.,
Baerbel Allingham, M.S. and
James Robinson, M.Ed.
OBJECTIVE: This study examined data on patients with serious and persistent mental illness in a large state hospital system to determine whether patients who took second-generation antipsychotics were more likely to develop diabetes mellitus than patients who took first-generation antipsychotics. METHODS: A case-control study design was used. A new prescription of an antidiabetic medication was used to identify new cases of diabetes mellitus. Odds ratios were calculated for exposure to second-generation antipsychotics (clozapine, risperidone, olanzapine, quetiapine, and multiple second-generation antipsychotics) compared with exposure to first-generation antipsychotics. Cases and controls were identified by using a database that contained drug prescription information from the inpatient facilities that were operated by the New York State Office of Mental Health. Data from January 1, 2000, to December 31, 2002, were examined. Among 13,611 unique patients who received antipsychotics, 8,461 met entry criteria of being hospitalized for at least 60 days and not having an antidiabetic medication prescribed in the past. A total of 181 of these inpatients received prescriptions for an antidiabetic medication at least 30 days after their admission. Eight controls (N=1,448) for each case (N=181) were matched by calendar year, length of observation period, race, age group, and diagnosis, giving a total sample of 1,629 patients. RESULTS: Statistically significant elevations in risk were seen among patients who received more than one second-generation antipsychotic or clozapine or quetiapine, compared with patients who received first-generation antipsychotics alone. Although not statistically significant, odds ratios for olanzapine and risperidone were also elevated. Conditional logistic regression adjusting for gender and age did not change the results. CONCLUSIONS: Exposure to multiple second-generation antipsychotics or clozapine or quetiapine significantly increased the risk of treatment-emergent diabetes mellitus.
This article has been cited by other articles:
|
|
|
|
 
M. Smith, D. Hopkins, R. C. Peveler, R. I. G. Holt, M. Woodward, and K. Ismail
First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis
The British Journal of Psychiatry,
June 1, 2008;
192(6):
406 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. U. Correll, C. Rummel-Kluge, C. Corves, J. M. Kane, and S. Leucht
Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials
Schizophr Bull,
April 21, 2008;
(2008)
sbn018v2.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. M. van Nimwegen, J. G. Storosum, R. M. E. Blumer, G. Allick, H. W. Venema, L. de Haan, H. Becker, T. van Amelsvoort, M. T. Ackermans, E. Fliers, et al.
Hepatic Insulin Resistance in Antipsychotic Naive Schizophrenic Patients: Stable Isotope Studies of Glucose Metabolism
J. Clin. Endocrinol. Metab.,
February 1, 2008;
93(2):
572 - 577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. L Citrome, R. I. Holt, W. M Zachry, J. D Clewell, P. A Orth, J. L Karagianis, and V. P. Hoffmann
Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics
Ann. Pharmacother.,
October 1, 2007;
41(10):
1593 - 1603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Citrome, A. Jaffe, J. Levine, and D. Martello
Incidence, Prevalence, and Surveillance for Diabetes in New York State Psychiatric Hospitals, 1997-2004
Psychiatr Serv,
August 1, 2006;
57(8):
1132 - 1139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Tarrant
Blood glucose testing for adults prescribed atypical antipsychotics in primary and secondary care
Psychiatr. Bull.,
August 1, 2006;
30(8):
286 - 288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. G. Holt, C. Bushe, and L. Citrome
Diabetes and schizophrenia 2005: are we any closer to understanding the link?
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
56 - 65.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Bushe and C. Paton
The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link?
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
76 - 83.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. B. Dickerson, R. W. Goldberg, C. H. Brown, J. A. Kreyenbuhl, K. Wohlheiter, L. Fang, D. Medoff, and L. B. Dixon
Diabetes Knowledge Among Persons With Serious Mental Illness and Type 2 Diabetes
Psychosomatics,
October 1, 2005;
46(5):
418 - 424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Parker
Use of Long-Acting Risperidone
Psychiatr Serv,
January 1, 2005;
56(1):
105 - 106.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Citrome, A. Jaffe, and J. Levine
Testing for diabetes
The British Journal of Psychiatry,
January 1, 2005;
186(1):
78 - 78.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2004
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
